---
document_datetime: 2024-10-17 15:45:21
document_pages: 19
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/aldurazyme-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: aldurazyme-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 14.1253562
conversion_datetime: 2025-12-27 16:25:57.469755
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Aldurazyme

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                                            | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0090              | Update of section 4.8 of the SmPC in order to update information on immunogenicity, based on results of completed clinical studies as well as results from the MPS I Registry. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 05/09/2024                          |                                             | SmPC                             | The MPS I Registry provided supplementary information into immunogenicity. Specifically, it has been noted that patients with severe phenotypes develop higher Anti-Drug Antibody (ADA) levels and elevated IgG antibody titres may impact the efficacy of the therapeutic enzyme, laronidase. Additionally, a small number of patients were tested positive for IgE antibodies, which may be associated with hypersensitivity or anaphylactic reactions. |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| N/0089   | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                           | 30/07/2024   |     | PL                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-----|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0088  | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                                                                                           | 13/02/2024   | n/a |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| II/0085  | To update section 4.2 of the SmPC in order to add home infusion upon request by PRAC following the assessment of procedure PSUSA/00001830/202104 based on literature review. The Package Leaflet and Annex II are updated accordingly. The RMP version 1.3 has also been submitted. C.I.3.b - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Change(s) with new additional data submitted by the MAH | 25/01/2024   |     | SmPC, Annex II and PL | SmPC new text: Section 4.2 Home Infusion Infusion of Aldurazyme at home may be considered for patients who are tolerating their infusions well and have no history of moderate or severe IARs for a few months. The decision to have a patient move to home infusion should be made after evaluation and upon recommendation by the treating physician. Home infusion infrastructure, resources, and procedures, including training, must be established and available to the healthcare professional. Home infusion should be supervised by a healthcare professional who should be always available during the home infusion and for a specified time after infusion. Appropriate information should be given by the treating physician and/or nurse to the patient and/or caregiver prior to initiation of home infusion. Dose and infusion rate should remain constant while at home, and not be changed without supervision of a healthcare professional. If the patient experiences adverse reactions during the home infusion, the infusion process should be stopped immediately, and appropriate medical treatment should be initiated (see section 4.4). Subsequent infusions may need |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                     |            |     |                        | to occur in a hospital or in an appropriate setting of outpatient care until no such adverse reaction is present. For more information, please refer to the Summary of Product Characteristics.   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0086   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                      | 30/03/2023 |     | SmPC and PL            |                                                                                                                                                                                                   |
| IAIN/0087 | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                                                                          | 29/03/2023 |     | SmPC, Labelling and PL |                                                                                                                                                                                                   |
| IB/0084/G | This was an application for a group of variations. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting | 29/11/2022 | n/a |                        |                                                                                                                                                                                                   |
| IA/0083   | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                        | 08/08/2022 | n/a |                        |                                                                                                                                                                                                   |
| IB/0082   | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                              | 12/04/2022 | n/a |                        |                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| PSUSA/1830/ 202104   | Periodic Safety Update EU Single assessment - laronidase                                                                                                                                                                                                                                                                   | 02/12/2021   | n/a        |                       | PRAC Recommendation - maintenance   |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|-------------------------------------|
| N/0081               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                           | 09/11/2021   |            | PL                    |                                     |
| IB/0079              | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                               | 12/07/2021   | n/a        |                       |                                     |
| IA/0078/G            | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                             | 06/05/2021   | 15/11/2021 | Annex II and PL       |                                     |
| IB/0077/G            | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation | 22/12/2020   | n/a        |                       |                                     |
| WS/1829              | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.z - Changes (Safety/Efficacy) of Human and                                                                                                                               | 12/11/2020   | 15/11/2021 | SmPC, Annex II and PL |                                     |

<div style=\"page-break-after: always\"></div>

|           | Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                        |            |            |                        |                       |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------|
| IB/0075   | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                                                    | 22/06/2020 | n/a        |                        |                       |
| N/0074    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                       | 24/02/2020 | 15/11/2021 | PL                     |                       |
| IB/0073   | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting                                                                                                                                                                                                                                                 | 20/11/2019 | n/a        |                        | material/intermediate |
| II/0071/G | This was an application for a group of variations. B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure | 17/01/2019 | n/a        |                        |                       |
| IG/1003   | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                                                                                                                                                             | 20/12/2018 | 04/10/2019 | SmPC, Labelling and PL |                       |
| IB/0069/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                     | 11/12/2018 | n/a        |                        |                       |

<div style=\"page-break-after: always\"></div>

|                    | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised   |            |            |                 |                                   |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------------------------------|
| PSUSA/1830/ 201804 | Periodic Safety Update EU Single assessment - laronidase                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 29/11/2018 | n/a        |                 | PRAC Recommendation - maintenance |
| IAIN/0070/G        | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                                                                                                              | 08/10/2018 | 04/10/2019 | Annex II and PL |                                   |

<div style=\"page-break-after: always\"></div>

| N/0066    | change in labelling or package leaflet not with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 02/03/2018   | 04/10/2019   | Labelling   | Minor connected   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------|-------------------|
| IA/0067   | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 21/02/2018   | n/a          |             |                   |
| IB/0064/G | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation | 05/02/2018   | n/a          |             |                   |

<div style=\"page-break-after: always\"></div>

|           | starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation   |            |            |    | and/or limits of an AS,   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|---------------------------|
| IA/0065   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 19/12/2017 | n/a        |    |                           |
| N/0063    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 06/09/2017 | 04/10/2019 | PL |                           |
| N/0062    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 22/02/2017 | 04/10/2019 | PL |                           |
| IB/0061/G | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test                                                                                                                                                                                                                                                                                                                  | 10/01/2017 | n/a        |    | procedure                 |

<div style=\"page-break-after: always\"></div>

| II/0060   | B.III.1.b.5 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New/updated certificate from an already approved/new manufacturer using materials of human/animal origin for which a risk assessment on potential contamination with adventitious agents is required                 | 19/05/2016   | n/a        |                       |                                                                                                                                                                                                                       |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0059   | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                     | 22/12/2015   | n/a        |                       |                                                                                                                                                                                                                       |
| II/0057   | B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol                                                              | 17/12/2015   | n/a        |                       |                                                                                                                                                                                                                       |
| IB/0058/G | This was an application for a group of variations. B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place | 16/12/2015   | n/a        |                       |                                                                                                                                                                                                                       |
| S/0054    | 12th Annual Re-assessment                                                                                                                                                                                                                                                                                               | 22/10/2015   | 16/12/2015 | SmPC, Annex II and PL | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that the Marketing |

<div style=\"page-break-after: always\"></div>

|                    |                                                                                                                                                                                                                                                                                                                                                                                                                |            |     | Authorisation of Aldurazyme should be maintained. In addition, as all Specific Obligations have been fulfilled, the CHMP considered that there were no remaining grounds for the Marketing Authorisation to remain under exceptional circumstances.   |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/1830/ 201504 | Periodic Safety Update EU Single assessment - laronidase                                                                                                                                                                                                                                                                                                                                                       | 06/11/2015 | n/a | PRAC Recommendation - maintenance                                                                                                                                                                                                                     |
| IB/0055            | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                            | 14/07/2015 | n/a |                                                                                                                                                                                                                                                       |
| IA/0053            | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                  | 27/03/2015 | n/a |                                                                                                                                                                                                                                                       |
| PSUV/0052          | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                         | 04/12/2014 | n/a | PRAC Recommendation - maintenance                                                                                                                                                                                                                     |
| S/0051             | Annual re-assessment.                                                                                                                                                                                                                                                                                                                                                                                          | 25/09/2014 | n/a |                                                                                                                                                                                                                                                       |
| II/0049/G          | This was an application for a group of variations. to replace an analytical method used in control of the active substance and to amend the active substance specification. B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a | 25/04/2014 | n/a |                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|           | - Change in the specification parameters limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                                         |            |     | B.I.b.1.z and/or   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------|
| IG/0418   | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the                                                                                                                                                                                                                                                          | 11/04/2014 | n/a | PSMF location      |
| IA/0048   | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                               | 27/11/2013 | n/a |                    |
| S/0047    | Annual re-assessment.                                                                                                                                                                                                                                                                                                                                                                                      | 24/10/2013 | n/a |                    |
| II/0046   | Changes to the active substance manufacturing process. B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological medicinal product and is not related to a protocol                                                                                                                                               | 19/09/2013 | n/a |                    |
| IA/0043/G | This was an application for a group of variations. B.III.1.b.3 - Submission of a new or updated Ph. Eur. TSE Certificate of suitability - Updated certificate from an already approved manufacturer B.III.1.b.3 - Submission of a new or updated Ph. Eur. TSE Certificate of suitability - Updated certificate from an already approved manufacturer B.III.1.b.3 - Submission of a new or updated Ph. Eur. | 26/03/2013 | n/a |                    |

<div style=\"page-break-after: always\"></div>

|         | TSE Certificate of suitability - Updated certificate from an already approved manufacturer                                          |            |            |                                  |                                                                                                                                                                                                                                                               |
|---------|-------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0283 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                      | 22/03/2013 | n/a        |                                  |                                                                                                                                                                                                                                                               |
| IA/0044 | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure | 20/03/2013 | n/a        |                                  |                                                                                                                                                                                                                                                               |
| S/0041  | Annual re-assessment.                                                                                                               | 17/01/2013 | 18/02/2013 | SmPC, Annex II, Labelling and PL | The CHMP, having reviewed the evidence of compliance with the specific obligations submitted by the MAH and having re-assessed the benefit/risk profile of the medicinal product, concluded that the benefit/risk balance for the product remains favourable. |
| IB/0042 | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                    | 07/12/2012 | n/a        |                                  |                                                                                                                                                                                                                                                               |
| N/0040  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                    | 27/04/2012 | 18/02/2013 | PL                               |                                                                                                                                                                                                                                                               |
| S/0037  | Annual Re-assessment                                                                                                                | 22/09/2011 | 21/11/2011 | SmPC, Annex II, Labelling and PL | The CHMP, having reviewed the evidence of compliance with the specific obligations submitted by the MAH and having re-assessed the benefit/risk profile of the medicinal product, concluded that the benefit/risk balance for the product remains favourable. |
| IB/0039 | B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation                                                        | 09/11/2011 | n/a        |                                  |                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

| II/0038   | Changes to the manufacture of the active substance B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological medicinal a protocol                                                                | 22/09/2011   | 22/09/2011   |    | product and is not related to   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|----|---------------------------------|
| IA/0036   | A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                   | 19/05/2011   | n/a          |    |                                 |
| IA/0033/G | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test | 29/03/2011   | n/a          |    | procedure                       |
| N/0035    | Minor change in labelling or package leaflet not (Art. 61.3 Notification)                                                                                                                                                                                                                 | 28/03/2011   | n/a          | PL | connected with the SPC          |
| IA/0034   | B.III.1.a.2 - Submission of a new or updated Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                           | 25/03/2011   | n/a          |    |                                 |
| S/0031    | Annual re-assessment.                                                                                                                                                                                                                                                                     | 23/09/2010   | 28/09/2010   |    |                                 |

<div style=\"page-break-after: always\"></div>

| II/0030   | Changes to the manufacture of the drug substance B.I.c.1.b - Change in immediate packaging of the AS - Qualitative and/or quantitative composition for sterile and non-frozen biological/immunological ASs                                    | 24/06/2010   | 06/07/2010   |             |                                                                                                                                                                                                                                      |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0028   | To update the SPC and the PL with adverse event \"erythema\" and to include minor adjustments to bring SPC labelling and leaflet in line with QRD template version 7.3 10/2009 Update of Summary of Product Characteristics and Package Leaflet | 18/03/2010   | 27/04/2010   | SmPC and PL | As a result of PSUR assessment MAH proposed to update the Section 4.8 of the SmPC with the term 'erythema' and with corresponding changes in PL. Proposed changes were accepted by CHMP.                                             |
| IA/0029   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                 | 19/03/2010   | n/a          |             |                                                                                                                                                                                                                                      |
| II/0026   | Additional sites for the manufacture and control of the drug product. Change(s) to the manufacturing process for the finished product                                                                                                         | 24/09/2009   | 06/10/2009   |             |                                                                                                                                                                                                                                      |
| S/0025    | Annual re-assessment.                                                                                                                                                                                                                         | 24/09/2009   | 01/10/2009   |             |                                                                                                                                                                                                                                      |
| IA/0027   | IA_16_b_Submission of new TSE certificate relating to active substance - other substances                                                                                                                                                     | 30/09/2009   | n/a          |             |                                                                                                                                                                                                                                      |
| II/0024   | Update of section 4.8 of the Summary of Product Characteristics (SPC) and relevant section of the Package Leaflet (PL) with regard to the adverse reactions, tachypnoea, cyanosis and extravasation.                                          | 29/05/2009   | 02/07/2009   | SmPC and PL | Following the CHMP requirement after the evaluation of the 7th Periodic Safety Update Report (PSUR) to review all cases of cyanosis, tachypnoea and extravasation, the MAH has performed a revision of these three adverse events in |

<div style=\"page-break-after: always\"></div>

|         | Additionally, local representative details have been updated in the PL. Update of Summary of Product Characteristics and Package Leaflet                                   |            |            | their global safety database. The results of this revision support the addition of information on extravasation, tachycardia and cyanosis to the product information.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0023 | Additional Quality Control testing facility. New reference standard with change to its storage conditions. Change(s) to the manufacturing process for the active substance | 23/10/2008 | 28/10/2008 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| S/0022  | Annual re-assessment.                                                                                                                                                      | 25/09/2008 | 01/10/2008 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| R/0021  | Renewal of the marketing authorisation.                                                                                                                                    | 19/03/2008 | 20/05/2008 | Based on the review of the available information, the CHMP considers that the benefit-risk balance of Aldurazyme remains positive. Due to inconsistencies in the PSURs submitted and the relatively low patient exposure, the PSUR should remain on a yearly cycle. Furthermore, Aldurazyme remains under exceptional circumstances due to one pending specific obligation regarding the MPS I Registry, by which the MAH commits to collect long term safety and efficacy data in patients treated with Aldurazyme as well as data on natural disease progression in untreated patients. Annual updates will be provided at the time of the annual reassessment. The benefit-risk balance of the product will continue to be reviewed annually as part of the Annual Re-assessments. The CHMP concluded that the renewal can be granted with unlimited validity. Changes were made to the product information to bring it |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |            |                       | in line with the current EMEA/QRD template. In addition, the list of local representatives in the PL has been revised to amend contact details for the representative of Romania.                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| S/0018  | Annual re-assessment.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 18/10/2007 | 20/12/2007 | SmPC, Annex II and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| IB/0020 | IB_38_b_Change in test procedure of finished product - minor change, biol. active subst./excipient                                                                                                                                                                                                                                                                                                                                                                                                            | 18/12/2007 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| II/0017 | Update of section 4.4, 4.8 and 5.1 of the Summary of Product Characteristics (SPC) and section 1, 2, 3 and 4 of the Package Leaflet (PL) to include the long term safety and efficacy results of the open label Extension Study ALID-006-01 which was completed and assessed during the third Annual Re-assessment (EMEA/H/C/0477/S/14). Furthermore, the PL has been amended to reflect the recommendation made during readability testing. Update of Summary of Product Characteristics and Package Leaflet | 20/09/2007 | 30/10/2007 | SmPC and PL           | Update of section 4.4 'Special warnings and precautions for use', 4.8 'Undesirable effects' and 5.1 'Pharmacodynamic properties' of the SPC and section 1 'What Aldurazyme is and what it is used for', 2 'Before you use Aldurazyme', 3 'How to use Aldurazyme' and 4 'Possible side effects' of the Package Leaflet (PL) to include the long term safety and efficacy results of the open label Extension Study ALID- 006-01 which was completed and assessed during the third Annual Re-assessment (EMEA/H/C/0477/S/14). Furthermore, the PL has been amended to reflect the recommendation made during the readability testing exercise. |
| II/0019 | Change(s) to the manufacturing process for the active substance                                                                                                                                                                                                                                                                                                                                                                                                                                               | 20/09/2007 | 27/09/2007 |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| II/0016 | Change(s) to the manufacturing process for the active substance                                                                                                                                                                                                                                                                                                                                                                                                                                               | 26/04/2007 | 02/05/2007 |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| II/0015 | Change(s) to the manufacturing process for the finished product                                                                                                                                                                                                                                                                                                                                                                                                                                               | 22/02/2007 | 28/02/2007 |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

| S/0014   | Annual re-assessment.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 16/11/2006   | 05/02/2007   | SmPC, Annex II, Labelling and PL   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0012  | This variation relates to an application for an update of section 4.2 (Posology and method of administration), 4.8 (Undesirable effects), 5.1 (Pharmacodynamic properties) and 5.2 (Pharmacokinetic properties) of the Summary of Product Characteristics (SPC) to include changes from the completion of the final study report (open label study in patients less than 5 years of age with MPS I). Additionally section 4.6 (Pregnancy and lactation) was updated to improve linguistics. In addition, the term \"rigors\" has being substituted in the SPC by \"chills\" as per the latest MedDRA version, as requested after the evaluation of the latest PSUR. Annex II was updated to reflect the finalisation of the mentioned study. Finally the package leaflet has been revised in accordance to the SPC changes and the list of the local representatives has been updated. Update of Summary of Product Characteristics and Package Leaflet | 27/04/2006   | 31/05/2006   | SmPC, Annex II and PL              | At the time of the initial Marketing Authorisation approval, the CHMP requested that the MAH should determine whether patients under 5 years of age would benefit from Aldurazyme treatment and the Marketing Authorisation Holder (MAH) undertook the commitment of submitting the clinical report of a phase II, open-label study conducted in children under the age of 5 years, which was ongoing at the time of the Marketing Authorisation Application (MAA). The MAH submitted the clinical study repot of the mentioned study and applied for an update of section 4.2 (Posology and method of administration), 4.8 (Undesirable effects), 5.1 (Pharmacodynamic properties) and 5.2 (Pharmacokinetic properties) of the Summary of Product Characteristics (SPC) to include changes from the completion of the study. Annex II (list of specific obligations) was updated to reflect the finalization of the mentioned study. The package leaflet was revised in accordance to the SPC changes and the list of the local representatives was updated. |
| II/0013  | Change(s) to the manufacturing process for the active substance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 27/04/2006   | 03/05/2006   |                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| S/0010   | Annual re-assessment.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 13/10/2005   | 19/01/2006   | Annex II                           | The CHMP having reviewed the evidence of compliance with the Specific Obligations submitted by the MAH and having                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |            |                       | re-assessed the benefit/risk profile of Aldurazyme, concluded that the benefit/risk of the product remains favourable in the approved indication.The CHMP agreed that the Marketing Authorisation should be kept under exceptional circumstances and agreed on a revised list of Specific Obligations.                                                                                                                                                                                                                                                                                                                                                               |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0011 | Change(s) to the manufacturing process for the finished product                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 17/11/2005 | 25/11/2005 |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| II/0009 | Change(s) to the manufacturing process for the active substance                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 23/06/2005 | 30/06/2005 |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| II/0008 | The Marketing Authorisation Holder applied for changes to section 4.4 (Special warnings and special precautions for use) and section 4.8 (Undesirable effects) of the Summary of Product Characteristics (SPC) to include safety information as a result of the 2nd PSUR assessment covering the period from 31 October 2003 to 30 April 2004. The Package Leaflet (PL) was revised accordingly. In addition, minor linguistic corrections were made in Annex II. Update of Summary of Product Characteristics and Package Leaflet | 17/02/2005 | 22/03/2005 | SmPC, Annex II and PL | This variation concerned the update of sections 4.4 and 4.8 of the SPC and relevant sections of the PL to include safety information, following the assessment of the 2nd PSUR. The change to section 4.4 of the SPC was the addition of a warning regarding the monitor of patients with severe underlying upper airway involvement. The adverse events pyrexia, vomiting and rigors were added to section 4.8 of the SPC and the wording regarding the severe infusion related events in patients with underlying airway involvement was updated . This information was also reflected in the PL. In addition, minor linguistic corrections were made in Annex II. |
| S/0005  | Annual re-assessment.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 21/10/2004 | 12/01/2005 | SmPC and Annex II     | The CHMP having reviewed the evidence of compliance with the Specific Obligations submitted by the MAH and having re-assessed the benefit/risk profile of Aldurazyme, concluded that the benefit/risk of the product remains favourable in the approved indication. Minor changes were made to the SPC and PL.The CHMP agreed that the                                                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                          |            |            |      | Marketing Authorisation should be kept under exceptional circumstances and agreed on a revised list of Specific Obligations.   |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|--------------------------------------------------------------------------------------------------------------------------------|
| IB/0007 | IB_38_c_Change in test procedure of finished product - other changes                                                                                                                                                                                                                                                                                                     | 29/11/2004 | n/a        |      |                                                                                                                                |
| IB/0006 | IB_30_b_Change in supplier of packaging components - replacement/addition                                                                                                                                                                                                                                                                                                | 17/11/2004 | n/a        |      |                                                                                                                                |
| N/0004  | The Marketing Authorisation Holder (MAH) applied for the inclusion of additional local representatives of the MAH for all new Member States. The MAH also took the opportunity to introduce minor linguistic changes in the Greek, Finnish and Swedish package leaflet. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 24/05/2004 | 13/07/2004 | PL   |                                                                                                                                |
| II/0003 | Change(s) to the manufacturing process for the active substance                                                                                                                                                                                                                                                                                                          | 24/03/2004 | 31/03/2004 |      |                                                                                                                                |
| I/0002  | IB_42_a_01_Change in shelf-life of finished product - as packaged for sale                                                                                                                                                                                                                                                                                               | 28/11/2003 | n/a        | SmPC |                                                                                                                                |
| I/0001  | 15_Minor changes in manufacture of the medicinal product                                                                                                                                                                                                                                                                                                                 | 22/10/2003 | 30/10/2003 |      |                                                                                                                                |